Physician profile
James W Welsh
NPI 1336359876
$420,849.49
in general payments reported to CMS, 2019-2025
19 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $3,118 · 2021: $5,556 · 2022: $401K · 2023: $9,776 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,588 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Travel and Lodging: $1,310 · Food and Beverage: $867 · Education: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,588.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Travel and Lodging | $1,309.64 |
| Food and Beverage | $866.53 |
| Education | $850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $394,573.80 | 2022 | |
| Roche Molecular Systems, INC. | $6,824.64 | 2021-2023 | |
| Reflexion Medical, INC. | $5,556.01 | 2021-2022 | |
| Novocure INC. | $4,535.43 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,132.00 | 2019-2020 | |
| Genentech, INC. | $2,800.00 | 2021 | |
| Iba Proton Therapy, INC. | $1,413.01 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,247.00 | 2019 | |
| Stemline Therapeutics INC. | $241.10 | 2025 | Orserdu |
| Zap Surgical Systems, INC. | $160.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.66 | 2019 | |
| Accuray Incorporated | $112.92 | 2022 | |
| Viewray Technologies INC | $107.88 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Welsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.